Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results ● Q2 Revenue of $9.1 million ● Q2 Income from Continuing Operations of $0.3 million ● Q2 Thyroid volume year-over-year increase of 6% ● Q2 Thyroid revenue year-over-year increase of 9%

Event · Earnings
Original reporting
Published Aug 12, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IDXG
Bullish
medium confidence
Mentioned
$IDXG
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IDXGBullishMed
01

Why it matters

Q2 results show pro forma gross margin and Adjusted EBITDA margin expansion, alongside operational efficiency improvements (turnaround time, DSO) and continued thyroid franchise growth, plus a planned CSO hire and ongoing pancreatic program development.

02

Market read

Traders can reassess near-term profitability trajectory and operational efficiency after the PancraGEN exit, while monitoring whether thyroid growth and cash collections stabilize.

03

What to watch

The pancreatic cancer program is not expected to contribute revenue in 2026 and remains un-cleared/ un-approved by FDA, so near-term valuation may still hinge on thyroid execution and working-capital trends.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 12, 2026 for Q2 results ended June 30, 2026

Background

Interpace is now a thyroid-only molecular diagnostics company after discontinuing its PancraGEN pancreatic testing business in May 2025.

Company-level read

Ticker impact

$IDXGBullishMedium confidence
Context

Interpace reported Q2 2026 revenue of $9.1M and pro forma gross margin expansion to 62% after discontinuing PancraGEN in May 2025.

Expected impact

Near-term bias modestly positive on margin/efficiency progress, but limited upside unless investors see accelerating thyroid growth or clearer pancreatic program milestones.

Evidence & confidence

The filing provides fresh quarterly financial datapoints (revenue, gross margin, operating income, Adjusted EBITDA) and operational KPIs (DSO, turnaround time, accounts/volume) plus a new CSO appointment and pancreatic program timeline expectations.

Market effects

Signals improving profitability potential for molecular diagnostics focused on thyroid testing, with operational leverage from lab automation.

No specific regional market linkage beyond US healthcare diagnostics demand.

Limited direct global read-through; primarily US-focused reimbursement and FDA clearance pathway.

Counterpoint

Revenue is essentially flat (Q2 $9.1M vs $9.2M prior year) and cash collections declined, so margin gains may not translate into sustained top-line momentum.

Key entities

  • Interpace Biosciences, Inc.

    OTCQX-listed IDXG, reporting Q2 2026 thyroid-only molecular diagnostics results and business update.

  • Chris McCarthy

    CFO quoted on Q2 revenue, margin expansion, and lab automation scaling.

  • Tom Burnell

    CEO quoted on durability of transition and platform combination strategy.

  • ThyGeNEXT and ThyraMIR v2

    Interpace’s mutation detection and microRNA pathway insight platforms referenced as drivers of commercial execution.

Related articles

$IDXGMed

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue ● Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million ● Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 ● Expected ye

$ZTEKFMed

Zentek Ltd. (ZTEKF): Financial results for FY2027

Zentek Ltd. (ZTEKF) furnished an SEC Form 6-K — earnings release. Zentek Q2 Fiscal 2027 Results News Release Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026 Guelph, Ontario, November 16, 2026. Ze

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.